Kornimate/medical-research-clean huggingface dataset:
abstats: computer-aided, non-invasive, acoustic gastrointestinal surveillance (agis) in acute pancreatitis

Conditions: Pancreatitis

Summary: the purpose of this study is to conduct a pilot test of an abdominal acoustic sensor on patients with acute pancreatitis to determine the correlation of acoustic signals with symptoms reported by the patient.

this study will use the abstats device, that measure iaas (intraabdominal acoustic signals) and intestinal rate and will correlate this data with symptoms reported by patients hospitalized for acute pancreatitis. the abstats multi-sensor wireless abdominal monitoring system includes low profile acoustic sensors that are applied to the anterior abdominal wall with tegaderm and monitors sounds emanating from the gi tract. the acoustic sensors continuously and non-invasively monitor and capture audio signals representing gi and abdominal wall function. the captured data is recorded in a synchronized manner from all sensors. we will place the abstats sensor on all patients immediately after admission to the hospital. only study staff trained on the abstats system will apply the sensors, which fit externally around the abdomen. a physician member of our study staff will be available at all times to help position the device if needed. we will continuously record abstats acoustic signals for the duration of the hospitalization, with the option to discontinue as clinically required or requested by the provider or patient. a research coordinator will collect clinical data from medical records and enter the data into a secure spreadsheet on csmc servers. patients will be asked to keep a daily diary of symptoms. in this diary, the patients will be asked to record information about their food consumption (if any), bowel movements (if any and if associated with contrast from ct imaging or with the use of suppositories/ laxative), specific symptoms, and whether the sensor was removed for any period of time during the day. this will allow us to compare the data collected by the abstats sensor with self-reported symptoms noted by patients. physicians and nurses will not be made aware of the abstats readings so as to eliminate the hawthorne effect. patients will be managed according to standard-of-care practice and the data collected by the abstats device will not be incorporated into clinical care.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * diagnosis of acute pancreatitis; must meet at least 2 out of the 3 following critiera: 1. abdominal pain consistent with acute pancreatitis 2. serum amylase/lipase \>3 times upper limit of normal 3. characteristic findings from abdominal imaging * able to provide informed consent exclusion criteria: * unable to provide consent * transfer patients * cognitive inability to follow directions to maintain sensors in place * unable to place abdominal sensors on patients * abdominal cellulitis * pregnant women

Keywords: pancreatitis acoustic sensor
odyssey: a study to investigate the efficacy of tradipitant in treating severe or critical covid-19 infection

Conditions: Coronavirus Infection

Summary: this is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical covid-19 infection. on evaluation for enrollment, participant will need to meet all inclusion and exclusion criteria. if participant consents, they will be randomized 1:1 to treatment with either tradipitant 85 mg po bid or placebo in addition to standard of care for covid-19 infection as per the protocol at the treating hospital. news 2 will be assessed at screening and daily following randomization. inflammatory lab markers as detailed should be collected once per day in the morning, preferably at the same time every morning. all enrolled participants will have whole blood collected for whole genome sequencing.


Eligibility criteria:
inclusion criteria: * adults aged 18-90 * confirmed laboratory covid-19 infection by rt-pcr * meeting severe or critical criteria of covid-19 infection as defined at treating hospital * confirmed pneumonia by chest radiograph or computed tomography * fever defined as temperature ≥ 36.6 °c armpit, ≥ 37.2 °c oral, or ≥ 37.8 °c rectal * oxygen saturation less than 92% exclusion criteria: * recent use of illicit drugs or alcohol abuse * known allergy to tradipitant or other neurokinin-1 antagonists * pregnancy * known hiv, hbv, or hcv infection * malignant tumor, other serious systemic diseases * inability to provide informed consent or to have an authorized relative or designated person provide informed consent, or to comply with the protocol requirements
safety and efficacy of natalizumab in combination with avonex in the treatment of multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the purpose of this study is to determine if natalizumab in combination with avonex is safe and effective in delaying progression of individuals diagnosed with relapsing remitting multiple sclerosis (ms).


Eligibility criteria:
inclusion criteria: * diagnosis of ms as defined by mcdonald et al, criteria, # 1- 4 * between the ages of 18 and 55, inclusive * baseline edss score between 0.0 and 5.0, inclusive * have been treated with avonex for at least the 12 months prior to randomization * have experienced at least one relapse (while on avonex) within the 12 months prior to randomization. * cranial mri scan demonstrating lesions consistent with ms. * have given written informed consent to participate in the study. exclusion criteria: * primary progressive, secondary progressive, or progressive relapsing ms. * ms relapse has occurred within 50 days of randomization * a clinically significant infectious illness within 30 days prior to randomization * history of, or abnormal lab result, indicative of significant disease, that in the opinion of the investigator, would preclude the administration of a recombinant humanized antibody immunomodulating agent or avonex for 116 weeks. * history of severe allergic or anaphylactic reactions or known drug hypersensitivity. * unable to perform the timed 25-foot walk, 9hpt and pasat 3 * abnormal blood tests at screening visit

Keywords: multiple sclerosis ms
role of serum regucalcin in diagnosis of hepatocellular carcinoma

Conditions: Role of Serum Regucalcin in Diagnosis of HCC

Summary: although the diagnosis and therapy of hcc have being improved, the poor prognosis still remains. to reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with hcc tumor progression and may be useful as potential diagnosis or therapeutic targets. smp30 (senescence marker protein 30)(serum regucalcin), which we have previously identiﬁed from guangxi hcc cdna expression library by the serex approach, is one of the hepatocellular carcinoma associated antigens \[4\] serum antibody response to smp30 in various patients using the methods of western-blot and elisa and showed that antibody to smp30 existed mainly in hcc patients (39.8%), especially in the one with alpha-fetoprotein (afp) negative


Eligibility criteria:
inclusion criteria: 1. newly diagnosed cases of hcc (be based on nccn guidelines triphasic ct and afp or liver biopsy) 2. adult patients 3. both genders are eligible. 4. informed consent obtained from subject or subject's legal representative exclusion criteria: 1. patient with other malignancies. 2. patients with advanced comorbidities except for renal failure. 3. prior chemotherapy
efficacy and safety comparison of steroid or placebo in combination with salmeterol and tiotropium in copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this efficacy and safety study compares four different combinations of blinded inhaled steroid treatments on top of open-label tiotropium and salmeterol in patients with chronic obstructive pulmonary disease (copd). the primary objective is the effect on lung function parameters.


Eligibility criteria:
inclusion criteria: * relatively stable, moderate to severe copd * male or female patients 40 years of age or older. * current or ex-smokers with a smoking history of more than 10 pack years exclusion criteria: * other significant disease that can influence the study results or be a safety risk for the patient * other medication that can influence the study results * hypersensitivity to the study medication * patients with unstable copd
assessment of adherence, quality of life, clinical response and safety of daily and long-acting growth hormone therapy

Conditions: Growth Hormone Deficiency; Growth Hormone Treatment

Summary: the purpose of the study is to compare quality of life, adherence, insulin resistance, body composition and efficacy of long-acting growth hormone (lagh) to daily growth hormone (dgh) in children with growth hormone deficiency (ghd). these objectives will be evaluated every 6 months for subjects prior to switch from dgh to lagh, and 6 months after.

daily subcutaneous injections of recombinant human growth hormone (gh) is the standard of care therapy for children with gh deficiency (ghd). a potential impediment to long-term efficacy of daily gh (dgh) is a lack of adherence and persistence. multiple long-acting growth hormone (lagh) molecules are being developed with the expectation that reduced frequency of injections will improve the patient and caregiver experience leading to improved adherence and, ultimately, improve efficacy. however, the connection between reduced injection frequency, improved adherence and improved efficacy have not yet been demonstrated. gh has metabolic effects that impact insulin resistance, body composition and lipid levels. there is concern that persistently elevated levels of gh provided by lagh may have a negative effect on metabolism. there is also concern that the larger size of the lagh molecules in development may limit their access to the target tissues leading to an imbalance of the linear growth and metabolic effects. the purpose of the study is to compare quality of life, adherence, insulin resistance, body composition and efficacy of long-acting growth hormone (lagh) to daily growth hormone (dgh) in children with growth hormone deficiency (ghd). these objectives will be evaluated every 6 months for subjects prior to switch from dgh to lagh, and 6 months after.

Eligibility criteria:
inclusion criteria: * girls must be between the ages of 2 and 11 years, and boys must be between the ages of 2 and 13 years * have established diagnosis of pediatric growth hormone deficiency (ghd). for the purposes of the study, ghd is defined as peak growth hormone response to clonidine/arginine stimulation testing of \<10 ng/ml * either treatment-naive or currently treated with a daily growth hormone as approved by health insurance exclusion criteria: * any medical condition which, in the opinion of the investigator, can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment * current treatment with long-acting growth hormone * currently pregnant or breastfeeding
taxol® in monotherapy or in combination with topotecan or carboplatin in patients with epithelial ovarian cancer in early relapse

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Malignant Tumor of Peritoneum

Summary: this study will look at the efficacy and safety of weekly administration of paclitaxel (taxol®) in monotherapy compared to paclitaxel in combination with topotecan or carboplatin in patients with ovarian cancer in early relapse.

the main purpose of this research study is to find out if treatment of early relapse of ovarian or fallopian tube or peritoneal cancer with paclitaxel (taxol\*) weekly administered, in lower doses in combination with topotecan (hycamtin\*) or carboplatin will improve efficacy compared to weekly administration of paclitaxel in monotherapy. tolerance in the three groups will be compared.

Eligibility criteria:
inclusion criteria: * patients aged \> 18 * histologically proven diagnosis of cancer of the ovary, the fallopian tube or peritoneum * peritoneal and/or nodes and/or visceral metastases * disease in progression under treatment or within 6 months after a first or second platinum-based line * a period of 3 weeks between last chemotherapy and inclusion * measurable disease (response evaluation criteria in solid tumors \[recist\] criteria) or cancer antigen (ca) 125 assessable disease (gynecologic cancer intergroup \[gcig\] criteria) * ecog performance status \< 2 * life expectancy of at least 12 weeks exclusion criteria: * previously received weekly administration of paclitaxel chemotherapy * involved in a trial within the last 30 days * previously received a bone marrow autogreffe or irradiation of the abdomen within 5 years, due to intensive chemotherapy * prior diagnosis of malignancy * history of ischemic cardiopathy, congestive heart failure (new york heart association \[nyha\] \> 2), arrhythmia, hypertension, or significant valvulopathy * pre-existing motor or sensory neurologic pathology or symptoms national cancer institute (nci) - common terminology criteria for adverse events (ctcae) grade \> 2 * bone marrow, renal, or hepatic insufficiency * severe active infection or occlusive or sub-occlusive disease * history of symptomatic brain metastases * fertile women not using adequate contraceptive methods * pregnant or breast feeding women * hypersensitivity to compounds chemically related to paclitaxel, topotecan, or carboplatin

Keywords: relapse within 6 months previously received taxane derivative
study of ofatumumab and eshap for the treatment of hodgkin's lymphoma

Conditions: Hodgkin Disease

Summary: the aim of this study is to analyze the efficacy of o-eshap treatment for hodgkin's lymphome patients that have a first line chemotherapy treatment failure due to refractoriness, partial response or relapsed. in the same way, mortality, global survival and free-progression survival after o-eshap treatment and taph will also analyzed.

in addition to the above: * to asses the complete response rate after o-eshap. * to asses the toxicity of o-eshap regimen * to asses the stem cells mobilization capacity of o-eshap regimen * to evaluate the final results of the whole procedure (o-eshap followed by high-dose chemotherapy and asct): transplant-related mortality (trm), overall survival (os), and progression free survival (pfs) * to investigate the correlation between the overall response and cd20 expression by tumoral cells.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed relapsed, partial response or refractory classical hl after first line chemotherapy. they will be included irrespective of cd20 expression on hrs cells. cd20 expression will be analyzed on all available biopsies and this data will be recorded for further evaluation. * age 18 to 65 years. patient \>65 and \<70 years old with ecog \< 2 and absence of comorbidities will be included in the study if considered adequate by the investigator. * leucocytes \> 3,0 x 109/l and platelets \> 100 x 109/l. * ecog \< 2. * no major organ dysfunction. * written informed consent. * hiv negative. * no active hepatitis b or c infection. * availability of histological report of biopsy at diagnosis or at relapse and availability of biopsy to be revised by reference pathologists. * absence of other neoplasia, except basocellular tumor or carcinoma of the uterine cervix in situ. * contraception measures in fertile females. exclusion criteria: * subjects who have current active hepatic or biliary disease * presence of pathology that would contraindicate the administration of chemotherapy * hiv positive * hepatitis b or c infection * history of other malignancies in addition to those specified in the inclusion criteria * informed consent not signed * pregnant and / or breast-feeding or reproductive capacity adults who do not use an effective method of birth control during study treatment and at least six months later. an effective method is that used at least one barrier mechanism.

Keywords: hodgkin ofatumumab lymphoma
the effect of neurolingualistik programming (nlp) on pain score, fear of pain and pain catastrophizing before colposcopy

Conditions: Pain, Acute

Summary: colposcopy, evaluation of cervical cytological abnormalities and it is the gold standard procedure for the early diagnosis of preinvasive and invasive diseases. despite her essentially a minimally invasive intervention, even referring the patient to colposcopy can cause significant anxiety and distress in patients. increased anxiety can also lead to deterioration in health-related quality. studies have been conducted to reduce the anxiety of women undergoing colposcopy, but there are no publications on topics such as anxiety, pain perception, and pain catastrophizing. neuro linguistic programming (nlp) has been called "the art and science of personal excellence", "the study of subjective experience". nlp helps us understand the difference between our actions that produce mediocre results or failure and those that require success or excellence. nlp: "how do i do something i do well?", "how can i do it better?", "how can i gain skills that i admire in others? it addresses questions like ". it is important to note that nlp is not limited to observable behavior. our way of thinking, that is, all experience and it also includes the mental processes that control our actions. by dealing with the entire structure of a person's experience (in fact, their motivation), it tries to shape the thought processes, emotions and beliefs that result in a behavior. it is especially about our communication with ourselves as well as with others. no study was planned on pain and pain perception during colposcopy by teaching the nlp technique to the patients.


Eligibility criteria:
inclusion criteria:those who are over 18 years of age and are not pregnant with an indication for colposcopy; those who agreed to participate in the study, exclusion criteria:patients who understand and can speak turkish patients who did not meet the inclusion criteria or had previously undergone colposcopy - -

Keywords: pain nlp colposcopy
the effect of the nature and frequency of a stimulation on the amplitude of the temporal summation of pain

Conditions: Healthy

Summary: temporal summation is a mechanism that enhances pain perception. it is a natural mechanism present in most individuals. generally, temporal summation is measured by the application of a moderately painful stimulation for several seconds.however, there is still no official recommendation in the literature. there is therefore a great disparity in the protocols. some studies apply thermal stimulation (heating the skin) while others apply mechanical stimulation (applying pressure). another point of contention is that some studies apply continuous stimulation for 2 minutes while others apply a series of several small stimulation of 1 second). between these studies, the amplitude of temporal summation varies according to the stimulation performed. note also that the study population is also very different between studies. in these conditions, it remains difficult to know the impact of the nature of the stimulation on the measured amplitude of the temporal summation.

objective: to determine the effect of the nature and frequency of the stimulation used to measure one of the physiological mechanisms of pain methods: in order to meet the objective, 34 pain-free participants will be recruited (17 females and 17 males) between the ages of 18 and 30 years. a single visit will be proposed (approximately 1 h). each participant will be stimulated with 4 stimulation conditions: * continuous thermal (1 stimulation of two minutes) * repetitive thermal (30 stimulations of 1 second) * continuous mechanical (1 stimulation of two minutes) * repetitive mechanical (30 stimulation of 1 second) in order to control certain psychological parameters, questionnaires measuring anxiety, depression and fear of pain will be administered. this will allow the investigation team to perform subgroup analyses if necessary. a repeated measures analysis of variance will be performed to meet the objective. anticipated results: the objective of this project is to determine the impact of different stimuli on the measurement of a pain mechanism. in this sense, the results will be important since they will allow to develop recommendations to optimize the measurement of this mechanism.

Eligibility criteria:
inclusion criteria: * subjects aged 18 to 30 years, able to consent (understand english or french) * no chronic pain * no primary sensory disorders exclusion criteria: * presence of upper extremity injuries * absence of anxiety symptoms (hads score \< 6) (appendix 1) * presence of cardiovascular disease / neurocognitive disorders / mental illness * pregnant or postpartum women less than one year old

Keywords: temporal summation mechanical stimulation heat pain stimulation thermode
exosome treatment and hair growth

Conditions: Alopecia Androgenica

Summary: this study investigates a novel exosome-based plant formulation for treating male pattern baldness (androgenetic alopecia), a condition that affects self-esteem and well-being. current treatments like minoxidil and finasteride offer limited effectiveness and may cause side effects, increasing demand for safer, more effective alternatives. exosomes, small extracellular vesicles that facilitate cell repair and communication, show promise in promoting hair regeneration. botanical extracts, such as ecklonia cava (brown seaweed) and thuja orientalis (medicinal plant), have also demonstrated hair growth benefits. this study combines these components into a single formulation to enhance therapeutic outcomes. a randomized, double-blind, placebo-controlled trial is conducted to evaluate the efficacy of this exosome-containing formulation. the study enrolls 20 male participants aged 18 to 35 with norwood 2-3 androgenetic alopecia. participants are randomly assigned to receive either the exosome treatment (containing 10 billion exosomes with ecklonia cava and thuja orientalis extracts) or a placebo (0.9% sodium chloride). the treatment is administered through four biweekly sessions of intradermal scalp injections, performed by a certified aesthetic physician under strict aseptic conditions. hair growth is assessed using standardized photography, trichoscopic imaging, and hair density measurements, with a blinded medical assessor ensuring objective evaluation. additionally, participants complete self-reported satisfaction surveys to gauge perceived effectiveness. strict ethical guidelines are followed, including informed consent and exclusion of individuals with underlying medical conditions, recent hair treatments, or lifestyle factors that could influence results. the study aims to provide scientific evidence on the safety and efficacy of this exosome-based therapy as a potential alternative for hair restoration.


Eligibility criteria:
inclusion criteria: 1. norwood grade 2-3 androgenic alopecia among male malaysians. 2. aged between 20 and 50 years. 3. demonstrated the ability to comprehend the study protocol and information provided by the investigators. 4. participants willing to give informed consent. exclusion criteria: 1. pre-existing thyroid disorders, bleeding disorders, or diabetes. 2. current use of any medical hair treatment. 3. corticosteroid or immunosuppressive drug use. 4. alopecia classified as norwood scale 1, 4, 5, 6, 7, or cicatricial alopecia. 5. smoking.

Keywords: alopecia